VIENNA (MedPage Today) -- A third of patients with treatment-resistant non-small cell lung cancer responded to second-line therapy with afatinib and cetuximab, investigators reported here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment